Skip to content

Multimodal mechanism of vagus nerve magnetic stimulation modulating the cerebral lymphoid system-meningeal lymphatic pathway to improve vascular cognitive impairment

Multimodal mechanism of vagus nerve magnetic stimulation modulating the cerebral lymphoid system-meningeal lymphatic pathway to improve vascular cognitive impairment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500111001
Enrollment
Unknown
Registered
2025-10-23
Start date
2025-11-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vascular cognitive impairment

Interventions

5Hz stimulation group:conventional rehabilitation treatment + 5Hz VNMS stimulation in the left mastoid area
20Hz stimulation group :conventional rehabilitation treatment + 20Hz VNMS stimulation in the left mastoid area

Sponsors

The First College of Clinical Medical Science, China Three Gorges University;Yichang Central People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Non-demented cognitive impairment after stroke (score on the Mini-Mental State Examination (MMSE): illiterate <=20, primary school literacy <=23, secondary school literacy <=27; Montreal Cognitive Assessment (MoCA) score <26) can cooperate with rehabilitation assessment and treatment. (Montreal Cognitive Assessment (MoCA) score <26) can co-operate with rehabilitation assessment and treatment; 2. Stable condition with no other medical history affecting cognitive function; 3. The duration of the disease is less than 6 months; 4. Age 55-80 years old; 5. Visual acuity and hearing ability to complete the relevant assessment; 6. Voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. cranial defects, with intracranial stents or pacemakers, etc. should not be treated with TBS; 2. accompanied by obvious dementia or mental disorder; 3. Combined with other related diseases that may affect the treatment, etc; 4. large cerebral infarction or haemorrhage, previous cerebrovascular disease or other diseases that affect cognitive function; 5. Combination of speech, visual and auditory impairment or communication difficulties that affect assessment and treatment; 6. Withdrawal from treatment midway.

Design outcomes

Primary

MeasureTime frame
Montreal Cognitive Assessment, MoCA;MRI (DTI-ALPS) examination;EEG;fNIRS examination;

Secondary

MeasureTime frame
Continuous performance task, CPT;Stroop-Color-and-Word-Test; N-back test;Event-related potential, ERP;BDNF;

Countries

China

Contacts

Public ContactSun Liangwen

The First College of Clinical Medical Science, China Three Gorges University; Yichang Central People’s Hospital

slw2013@sina.com+86 717 622 0809

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026